Skip to main content
Premium Trial:

Request an Annual Quote

FDA Clears GenePOC Group B Streptococcus Assay, MDx Platform

NEW YORK (GenomeWeb) – GenePOC today said that it has received FDA clearance to market its molecular assay for detecting Group B streptococcus and its Revogene molecular diagnostics instrument in the US.

The test and instrument was launched in Europe earlier in the year.

The GenePOC GBS LB assay uses real-time PCR technology to detect GBS colonization from lim broth samples. In clinical studies, the assay had overall sensitivity of 95.9 percent and specificity of 95.5 percent, compared with standard culture, the company said. Revogene, a fully automated, standalone system, allows labs to run between one and eight samples at once.

"The GenePOC GBS LB test will fulfill the increasing market need for cost-effective automated and easy-to-use testing for the identification of antepartum Group B Streptococcus colonization," GenePOC CEO Patrice Allibert said in a statement. He added that the firm is working to submit a second assay for Clostridium difficile to the FDA in the near future. 

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.